EFFECT OF KELTICAN AND POLARIZING LIGHT ON LIPID PEROXIDATION AND ANTIOXIDANT DEFENSES IN TYPE 2 DIABETES MELLITUS WITH DIABETIC POLYNEUROPATHY AND DYSLIPIDEMIA
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i3.9284Keywords:
diabetic polyneuropathy, oxidative stress, lipid metabolism, keltican, polarizing lightAbstract
Patients with type 2 diabetes mellitus (DM) suffer from dysfunction of lipid peroxidation processes, resulting in abnormal functioning of cell membrane structures, which leads to their increased destruction, and may be a factor in the progression of diabetic polyneuropathy (DPN) complication.
The aim of the study was to learn the effects of complex treatment with incorportion of the Keltican drug and polarizing light on LPO and AOP indicators in patients with type 2 diabetes with diabetic polyneuropathy and dyslipidemia.
Material and Methods. 130 patients with type 2 diabetes, complicated by diabetic polyneuropathy were examined. Patients were divided into 4 groups: 32 patients in group 1 received standard treatment, 32 patients in group 2 additionally received 1 capsule of Keltican three times a day for one month. For 35 diabetics of group 3, 12 therapeutic procedures were additionally assigned with polarizing light. 31 patients in the group 4, in addition to standard treatment, received Keltican combined with polarizing light therapy course.
The state of LPO was assessed by the content of conjugated dienes and malondialdehyde (MDA). The antioxidant protection (AOP) activity was studied by concentration of superoxide dismutase (SOD), catalase and glutathione reductase (SH-group).
Cholesterol levels, as well as fractions of HDL (high density lipoprotein), LDL (low density lipoprotein) and TG (triglycerides) were determined to assess lipid metabolism.
Results. Inclusion of Keltican and polarizing light in the standard treatment of DPN has a more pronounced effect on LPO and AOP compared to standard treatment. The results of lipidograms are most closely related to the target level under the influence of treatment in the group 4.
Conclusion. Inclusion of the drug Keltican and light therapeutic procedures in the standard therapy of DPN in patients with type 2 diabetes and dyslipidemia had an adjusting impact on LPO and AOP indicators.
